Akanda (AKAN) Competitors $1.10 -0.02 (-1.79%) Closing price 04/17/2025 03:55 PM EasternExtended Trading$1.14 +0.04 (+4.09%) As of 07:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock AKAN vs. AIM, GNPX, LIPO, AYTU, APLM, GTBP, CDT, FRTX, CANF, and NKGNShould you be buying Akanda stock or one of its competitors? The main competitors of Akanda include AIM ImmunoTech (AIM), Genprex (GNPX), Lipella Pharmaceuticals (LIPO), Aytu BioPharma (AYTU), Apollomics (APLM), GT Biopharma (GTBP), Conduit Pharmaceuticals (CDT), Fresh Tracks Therapeutics (FRTX), Can-Fite BioPharma (CANF), and NKGen Biotech (NKGN). These companies are all part of the "pharmaceutical products" industry. Akanda vs. AIM ImmunoTech Genprex Lipella Pharmaceuticals Aytu BioPharma Apollomics GT Biopharma Conduit Pharmaceuticals Fresh Tracks Therapeutics Can-Fite BioPharma NKGen Biotech Akanda (NASDAQ:AKAN) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, community ranking, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends. Do institutionals and insiders hold more shares of AKAN or AIM? 1.0% of Akanda shares are owned by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are owned by institutional investors. 20.4% of Akanda shares are owned by company insiders. Comparatively, 0.0% of AIM ImmunoTech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is AKAN or AIM more profitable? Akanda has a net margin of 0.00% compared to AIM ImmunoTech's net margin of -12,594.21%. Akanda's return on equity of 0.00% beat AIM ImmunoTech's return on equity.Company Net Margins Return on Equity Return on Assets AkandaN/A N/A N/A AIM ImmunoTech -12,594.21%-421.73%-147.54% Does the media refer more to AKAN or AIM? In the previous week, Akanda had 1 more articles in the media than AIM ImmunoTech. MarketBeat recorded 2 mentions for Akanda and 1 mentions for AIM ImmunoTech. Akanda's average media sentiment score of 0.44 beat AIM ImmunoTech's score of 0.00 indicating that Akanda is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akanda 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AIM ImmunoTech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation and earnings, AKAN or AIM? AIM ImmunoTech has lower revenue, but higher earnings than Akanda. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkanda$2.51M0.63-$32.28MN/AN/AAIM ImmunoTech$170K38.87-$28.96M-$0.31-0.29 Which has more volatility and risk, AKAN or AIM? Akanda has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Does the MarketBeat Community favor AKAN or AIM? AIM ImmunoTech received 59 more outperform votes than Akanda when rated by MarketBeat users. CompanyUnderperformOutperformAkandaN/AN/AAIM ImmunoTechOutperform Votes5983.10% Underperform Votes1216.90% Do analysts prefer AKAN or AIM? AIM ImmunoTech has a consensus target price of $2.75, indicating a potential upside of 2,908.75%. Given AIM ImmunoTech's stronger consensus rating and higher possible upside, analysts clearly believe AIM ImmunoTech is more favorable than Akanda.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akanda 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00AIM ImmunoTech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAkanda beats AIM ImmunoTech on 8 of the 15 factors compared between the two stocks. Get Akanda News Delivered to You Automatically Sign up to receive the latest news and ratings for AKAN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKAN vs. The Competition Export to ExcelMetricAkandaMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.57M$1.18B$5.31B$7.34BDividend YieldN/AN/A5.45%4.35%P/E RatioN/A10.0421.9417.81Price / Sales0.639.44380.6697.70Price / CashN/A10.4038.2534.62Price / Book-0.011.216.453.98Net Income-$32.28M-$56.07M$3.22B$247.75M7 Day Performance-5.16%4.48%0.74%0.28%1 Month Performance-28.10%-6.26%-9.66%-7.60%1 Year Performance-85.43%-40.03%11.81%1.46% Akanda Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKANAkandaN/A$1.10-1.8%N/A-85.4%$1.57M$2.51M0.00110AIMAIM ImmunoTech1.6085 of 5 stars$0.09-22.3%$2.75+2,908.8%-80.3%$6.61M$170,000.00-0.1920Gap DownHigh Trading VolumeGNPXGenprex4.4694 of 5 stars$0.26-0.8%$10.00+3,680.7%-88.7%$6.39MN/A0.0020Short Interest ↓News CoveragePositive NewsLIPOLipella Pharmaceuticals2.1677 of 5 stars$2.45+0.4%N/A-58.2%$6.25M$536,357.00-0.584Gap DownAYTUAytu BioPharma0.8342 of 5 stars$1.00-3.7%N/A-63.6%$6.17M$77.23M-0.69160Positive NewsGap UpAPLMApollomics1.6971 of 5 stars$5.63-5.4%$200.00+3,452.4%-87.4%$6.12M$1.22M0.0045Gap DownGTBPGT Biopharma3.5773 of 5 stars$2.29+2.7%$11.00+380.3%-38.5%$5.81MN/A-0.338Short Interest ↓Gap DownCDTConduit Pharmaceuticals0.2181 of 5 stars$0.87-4.6%N/A-99.8%$5.78MN/A-0.023Gap UpFRTXFresh Tracks TherapeuticsN/A$0.94-0.5%N/A+3.9%$5.59M$10.06M-0.6620CANFCan-Fite BioPharma2.1336 of 5 stars$1.30-17.2%$14.00+976.9%-39.4%$5.56M$667,000.00-0.738Gap DownHigh Trading VolumeNKGNNKGen BiotechN/A$0.12+4.3%N/A-88.5%$5.40M$80,000.00-0.02N/A Related Companies and Tools Related Companies AIM Competitors GNPX Competitors LIPO Competitors AYTU Competitors APLM Competitors GTBP Competitors CDT Competitors FRTX Competitors CANF Competitors NKGN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKAN) was last updated on 4/21/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akanda Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akanda With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AKAN Stock Free AKAN Stock Alerts